thebench.bio #1 Ecosystem for the Bio-Tech Industry

Regulatory Daily Summary

Regulatory Daily Summary: What Happened on November 19, 2026

FDA approves three treatments as UK proposes broader gene therapy rules

The FDA cleared drugs for Niemann-Pick disease, myasthenia gravis and Type 3 Gaucher disease. The White House also withdrew Heidi Overton’s nomination to lead the agency.

  • Updated
  • Read from 7 articles, 7 publications
  • P P +1

Today in brief

Beren’s Lembaz won FDA approval to lower mortality risk in eligible patients with infantile-onset Niemann-Pick disease type C.1 Regeneron’s Livsayis is now approved for some adults with myasthenia gravis, and Genzyme’s Infilbray for neurological symptoms of Type 3 Gaucher disease.23

The UK government proposed bringing some synthetic therapies and genome-editing treatments under its gene therapy rules.4

The White House withdrew Heidi Overton’s FDA commissioner nomination ahead of a scheduled Senate committee consideration.567

Lembaz approved to reduce mortality risk in Niemann-Pick disease

The FDA approved Beren’s Lembaz for patients who weigh at least 7 kg and whose neurological symptoms started before age 6.1 The drug is indicated to reduce mortality risk in patients with infantile-onset Niemann-Pick disease type C.1

The approval relied on a survival analysis of 36 treated patients across three clinical studies and an expanded access program.1 Compared with matched external controls, the analysis found a 55% lower mortality risk among treated patients.1 Diagnosing the disease can take years, making it difficult to identify patients who may qualify for treatment.1

UK proposal would bring some synthetic and genome-editing therapies under gene therapy rules

The UK proposed revising the legal definition of gene therapy medicines to cover certain synthetic therapies and genome-editing treatments under its existing advanced therapies framework.4 The proposal would amend the Human Medicines Regulations 2012, subject to international notification procedures and parliamentary approval.4

The Medicines and Healthcare products Regulatory Agency and the Department of Health in Northern Ireland consulted on the changes for six weeks. Eighty-three percent of respondents supported them.4 The government says the changes would clarify classification and regulatory requirements while keeping approval standards unchanged and avoiding reclassification of already licensed medicines.4

Livsayis approved for adults with antibody-positive myasthenia gravis

The FDA approved Regeneron’s Livsayis for adults with generalized myasthenia gravis who test positive for anti-AChR antibodies.2 The siRNA therapy is injected under the skin four times a year. It is intended to lower circulating factor 5 and reduce terminal complement activation.2

In the ongoing Phase 3 NIMBLE trial, patients taking Livsayis improved 4.5 points on the Myasthenia Gravis-Activities of Daily Living scale at week 24, compared with 2.2 points on placebo.2 The 2.3-point difference was statistically significant.2 At least 5% of patients reported injection-site reactions, urinary tract infections or viral infections.2

Infilbray becomes first approved treatment for neurological symptoms of Type 3 Gaucher disease

The FDA approved Genzyme’s Infilbray for neurological symptoms of Type 3 Gaucher disease in adults and children weighing at least 15 kg.3 The oral drug crosses the blood-brain barrier and inhibits glucosylceramide synthase, an enzyme involved in harmful-substance buildup.3

In a 43-patient study, participants taking Infilbray improved on a combined measure of ataxia and cognitive function after 52 weeks, compared with patients receiving enzyme replacement therapy.3 Reported risks include gastrointestinal and mood effects, suicidal thoughts and behavior, possible vision clouding in younger patients, and potential fetal-development harms during pregnancy.3

White House withdraws Overton’s FDA commissioner nomination

The White House withdrew Heidi Overton’s nomination before the Senate committee’s scheduled consideration on November 18.567 Three sources cited by Reuters said the nomination lacked sufficient congressional support. Senator Bill Cassidy said he believed Overton had enough support to pass both the committee and full Senate.67

Kyle Diamantas remains acting head of the FDA.6 A person familiar with discussions said Senator Roger Marshall had expressed interest in the role. Whether Marshall will be selected or secure Senate support remains uncertain.7

Also published